Demonstration of kappa 3-opioid receptors in the SH-SY5Y human neuroblastoma cell line

J Neurochem. 1995 Jul;65(1):170-5. doi: 10.1046/j.1471-4159.1995.65010170.x.


In addition to the mu- and delta-opioid receptors previously reported, the SH-SY5Y human neuroblastoma cell line has high levels of kappa 3 receptors, accounting for 40% of total opioid binding, as measured with [3H]-diprenorphine binding. Competition studies reveal binding profiles for all three receptor classes that are similar to those observed in brain membranes. Differentiation with retinoic acid increases the levels of opioid receptor binding in the cell line, with the largest elevations in kappa 3 binding. Fully 75% of the increased binding corresponds to kappa 3 sites, which represent 50% of total opioid receptor binding in differentiated cells. Morphine inhibits forskolin-stimulated cyclic AMP accumulation, and this effect is readily blocked by the mu antagonist D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP). Naloxone benzoylhydrazone, a kappa 3 agonist, inhibits forskolin-stimulated cyclic AMP accumulation more potently than morphine and is not reversed by CTAP. These studies indicate that SH-SY5Y cells contain high levels of functional kappa 3 receptors.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Binding Sites / drug effects
  • Binding, Competitive
  • Cell Differentiation
  • Cyclic AMP / antagonists & inhibitors
  • Diprenorphine / metabolism
  • Humans
  • Morphine / pharmacology
  • Naloxone / analogs & derivatives
  • Naloxone / pharmacology
  • Neuroblastoma / metabolism*
  • Neuroblastoma / pathology
  • Receptors, Opioid, kappa / metabolism*
  • Tretinoin / pharmacology
  • Tumor Cells, Cultured / drug effects


  • Receptors, Opioid, kappa
  • naloxone benzoylhydrazone
  • Diprenorphine
  • Naloxone
  • Tretinoin
  • Morphine
  • Cyclic AMP